The Cooper Companies/$COO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About The Cooper Companies
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
- Ticker
- $COO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15,000
- Headquarters
- San Ramon, United States
- Website
- www.coopercos.com
COO Metrics
BasicAdvanced
$11B
20.27
$2.90
0.82
-
Price and volume
Market cap
$11B
Beta
0.82
52-week high
$89.83
52-week low
$51.01
Average daily volume
2.6M
Financial strength
Current ratio
1.222
Quick ratio
0.506
Long term debt to equity
0.261
Total debt to equity
0.336
Interest coverage (TTM)
5.87%
Profitability
EBITDA (TTM)
907.5
Gross margin (TTM)
65.35%
Net profit margin (TTM)
13.46%
Operating margin (TTM)
12.36%
Effective tax rate (TTM)
-23.33%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
2.61%
Return on equity (TTM)
6.84%
Valuation
Price to earnings (TTM)
20.271
Price to revenue (TTM)
2.704
Price to book
1.34
Price to tangible book (TTM)
3.72
Price to free cash flow (TTM)
16.965
Free cash flow yield (TTM)
5.89%
Free cash flow per share (TTM)
3.471
Growth
Revenue change (TTM)
4.73%
Earnings per share change (TTM)
42.40%
3-year revenue growth (CAGR)
6.43%
10-year revenue growth (CAGR)
8.33%
3-year earnings per share growth (CAGR)
28.16%
10-year earnings per share growth (CAGR)
8.57%
What the Analysts think about COO
Analyst ratings (Buy, Hold, Sell) for The Cooper Companies stock.
Analyst projections of the future price of The Cooper Companies stock.
Bulls say / Bears say
CooperSurgical’s fertility business grew 5% organically in the third quarter, helped by genomics demand, new clinic wins and further adoption of its laboratory platform. This gives the company a growing business alongside contact lenses. (The Motley Fool)
There are pockets of strong demand in CooperVision’s newer products: MyDay posted double-digit growth in several markets, while MiSight grew 20% organically. New product launches could help extend that momentum, although the segment was flat overall in the quarter. (The Motley Fool)
Cash generation was strong, with record quarterly free cash flow of $273 million, up 66% year on year. Cooper also repurchased $339 million of shares in the quarter and increased its remaining buyback authorisation to about $1.5 billion. (CooperCompanies)
Weak contact-lens sales prompted Cooper to cut its 2026 revenue and adjusted-profit forecasts; third-quarter revenue also missed analysts’ expectations. The revised annual ranges were below prior guidance and analyst estimates, leaving a higher bar for a recovery. (Reuters)
The embryo-culture-media recall has led to a $271.6 million net litigation charge, with more than 1,500 claimants reported and most settlement payments expected in fiscal 2026. The matter creates a substantial cash cost as well as ongoing legal and reputational risk. (SEC)
CEO Albert White stepped down in October, and executive chair Robert Rosebrough is overseeing day-to-day operations while a permanent successor is sought. The leadership change adds execution uncertainty as Cooper works to revive contact-lens growth. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
COO Financial Performance
Revenues and expenses
COO Earnings Performance
Company profitability
Upcoming events
No upcoming events
COO News
AllArticlesVideos

ROSEN, A LEADING NATIONAL FIRM, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Newsfile Corp13 hours ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Newsfile Corp2 days ago

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Newsfile Corp4 days ago
Funds containing COO
AllUSDEURGBP
Fund name | Fund size | $COO weighting |
|---|---|---|
iShares Ageing Population£AGES | $887M | 0.45% |
iShares Ageing Population$AGED | $887M | 0.45% |
iShares Ageing Population€AGED | $887M | 0.45% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.20% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.